Strides Shasun gains 4% on USFDA approval for Potassium Citrate

Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Strides Shasun rose more than 4 percent intraday Tuesday on USFDA approval.

The company has received approval from the United States of Food & Drug Administration (USFDA) for Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq and 15 mEq.

The US market for Potassium Citrate is approximately USD 110 million, as per IMS data.

The company will be the second generic player to commercialize the product.

The product, which is the first approval for an extended release tablet for the company, will be launched immediately.

Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones.

Recently, the company's Bangalore facility received Establishment Inspection Report (EIR) from the USFDA, which was inspected in May 2017.

At 09:23 hrs Strides Shasun was quoting at Rs 978, up Rs 36.70, or 3.90 percent on the BSE.

Posted by Rakesh Patil